- Conditions
- Breast Cancer
- Interventions
- Bevacizumab, Standard adjuvant chemotherapy
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 44
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 40 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2521–2544
of 9,549
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
- Conditions
- Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
- Interventions
- Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 124
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease (ILD)
- Interventions
- ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator
- Device · Procedure
- Lead sponsor
- Tempus AI
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more
- Conditions
- Autism
- Interventions
- Autism Research
- Behavioral
- Lead sponsor
- Hon K. Yuen, PhD
- Other
- Eligibility
- 9 Years to 18 Years
- Enrollment
- 18 participants
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Vasomotor Symptoms, Postmenopausal Disorders
- Interventions
- JDS-HF 3.0, Placebo
- Dietary Supplement
- Lead sponsor
- Bonafide Health
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Lake Worth, Florida • Idaho Falls, Idaho
- Conditions
- Brain Tumors, Central Nervous System Tumors
- Interventions
- filgrastim, topotecan hydrochloride, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal
- Interventions
- EG-1962 (nimodipine microparticles), Enteral Nimodipine
- Drug
- Lead sponsor
- Edge Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 32 more
- Conditions
- Type 2 Diabetes, Vitamin D Deficiency
- Interventions
- Vitamin D2, Sugar pill
- Dietary Supplement · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Moderate to Severe Allergic Asthma
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Crescent City, California • Fresno, California + 47 more
- Conditions
- Chronic Prostatitis With Chronic Pelvic Pain Syndrome
- Interventions
- Tanezumab, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 17 more
- Conditions
- Dilated Cardiomyopathy, Lamin A/C Gene Mutation
- Interventions
- ARRY-371797 (PF-07265803), Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more
- Conditions
- Diastolic Heart Failure
- Interventions
- alagebrium, placebo
- Drug
- Lead sponsor
- Synvista Therapeutics, Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 27 more
- Conditions
- Progressive Supranuclear Palsy (PSP)
- Interventions
- ABBV-8E12, Placebo solution for IV infusion on Day 15
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 19 more
- Conditions
- ABDOMINAL AORTIC ANEURYSMS
- Interventions
- AneuRx AAA stent graft / Talent AAA stent graft
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 728 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 57 more
- Conditions
- HIV Infections
- Interventions
- MyPEEPS Mobile
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 13 Years to 18 Years · Male only
- Enrollment
- 764 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Chicago, Illinois • New York, New York + 1 more
- Conditions
- Percutaneous Coronary Intervention, Optical Coherence Tomography, In-stent Coronary Artery Restenosis
- Interventions
- Optical Coherence Tomography
- Device
- Lead sponsor
- Jesse Brown VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 10 more
- Conditions
- Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Interventions
- BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Transurethral Resection of Bladder Tumor, Gemcitabine
- Biological · Procedure · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 52 more
- Conditions
- Extensive-Stage Small Cell Lung Cancer
- Interventions
- Carboplatin, Palifosfamide-tris, Etoposide
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Los Angeles, California • Santa Rosa, California + 36 more
- Conditions
- Cushing's Syndrome
- Interventions
- mifepristone
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Escondido, California • Stanford, California + 13 more
- Conditions
- Breast Cancer
- Interventions
- Cisplatin, carboplatin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Pulmonary Embolism
- Interventions
- Denali inferior vena cava filter
- Device
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 18 more
- Conditions
- Chronic Kidney Disease, Anemia of Chronic Disease
- Interventions
- Oral Calcitriol 0.5 mcg once daily for 6 weeks, Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
- Interventions
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 6 Months to 11 Years
- Enrollment
- 4,338 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more